Turnstone Biologics (TSBX) Stock Price, News & Analysis

Company Overview

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Key Stats

• Today's Range: $0.33 to $0.36
• 50-Day Range: $0.33 to $0.42
• 52-Week Range: $0.33 to $3.39
• Volume: 19,333 shs
• Average Volume: 219,529 shs
• Market Capitalization: $7.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.45
• Consensus Rating: Reduce

Turnstone Biologics Stock Analysis - MarketRank™

Turnstone Biologics scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Turnstone Biologics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Turnstone Biologics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Turnstone Biologics are expected to grow in the coming year, from ($3.32) to ($0.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Turnstone Biologics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Turnstone Biologics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Turnstone Biologics has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.52% of the float of Turnstone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Turnstone Biologics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Turnstone Biologics has recently decreased by 2.97%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Turnstone Biologics does not currently pay a dividend.

Dividend Growth

Turnstone Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.52% of the float of Turnstone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Turnstone Biologics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Turnstone Biologics has recently decreased by 2.97%, indicating that investor sentiment is improving.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Turnstone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSBX Stock Analysis - Frequently Asked Questions

How have TSBX shares performed this year?

Turnstone Biologics' stock was trading at $0.4969 at the beginning of the year. Since then, TSBX stock has decreased by 33.6% and is now trading at $0.33.
View the best growth stocks for 2025 here.

How were Turnstone Biologics' earnings last quarter?

Turnstone Biologics Corp. (NASDAQ:TSBX) posted its earnings results on Friday, March, 28th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.13.

When did Turnstone Biologics IPO?

Turnstone Biologics (TSBX) raised $80 million in an initial public offering (IPO) on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share.

How do I buy shares of Turnstone Biologics?

Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Turnstone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Turnstone Biologics investors own include Cara Therapeutics (CARA), JPMorgan Chase & Co. (JPM), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Bank of America (BAC) and Intel (INTC).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 4/19/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSBX
• CIK: 1764974
• Web: turnstonebio.com
• Phone: 347-897-5988
• Fax: N/A
• Employees: 82
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $0.45
• High Stock Price Target: $0.50
• Low Stock Price Target: $0.40
• Potential Upside/Downside: +36.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-55,200,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -105.99%
• Return on Assets: -87.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.75
• Quick Ratio: 3.75

Sales & Book Value

• Annual Sales: $19.31 million
• Price / Sales: 0.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.27 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 23,139,000
• Free Float: 15,704,000
• Market Cap: $7.64 million
• Optionable: Not Optionable
• Beta: 1.30